advertisement
Abstract #17173 Published in IGR 9-1
Tafluprost. Prostanoid FP receptor agonist, antiglaucoma drug
Wang Y; Bolos J; Serradell NDrugs of the Future 2006; 31: 788-792
Prostaglandin analogues have been extensively studied and used for lowering/controlling the elevated intraocular pressure (IOP) that causes glaucoma. In the search for a drug candidate with stronger and more consistent IOP-lowering activity while producing milder side effects than currently available drugs, tafluprost was synthesized and selected for further evaluation. Preclinical studies carried out in mice, cats and monkeys showed that tafluprost at a concentration of 0.005% has a potent IOP-lowering effect. Pharmacokinetic studies demonstrated rapid absorption into ocular tissues and entry into the systemic circulation. Results from phase I and II clinical trials indicated that tafluprost had a stronger IOP-lowering effect than latanoprost, with fewer and milder local side effects. The compound has been submitted for regulatory approval in Japan by Santen.
Dr. Y. Wang, 8106 Runnymeade Dr., Frederick, MD 21702, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)